• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺炎球菌多糖-破伤风类毒素天然 C 片段缀合疫苗:载体效应和免疫原性。

The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity.

机构信息

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.

出版信息

Mediators Inflamm. 2020 Jul 4;2020:9596129. doi: 10.1155/2020/9596129. eCollection 2020.

DOI:10.1155/2020/9596129
PMID:32714092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7355367/
Abstract

The encapsulated bacteria, as , type b, and , cause serious morbidity and mortality worldwide. The capsular polysaccharide (PS), which could elicit a weak T cell-independent immune response, is a vital virulence determinant. One of the strategies to improve the PS-specific immunogenicity is to conjugate PS with a nontoxic carrier protein. Tetanus toxoid (TT) and CRM are the typical carrier proteins for the PS conjugate vaccines. TT is the inactivated tetanus toxin manipulated with formaldehyde, which suffers from the pollution from residual formaldehyde and the incomplete detoxification. CRM has the disadvantage of low-yield purification with the requirement of sophisticated culture conditions. Thus, a novel carrier protein without these disadvantages is highly required. The tetanus toxin native C-fragment (Hc) is safe, low-cost, and highly immunogenic with easy purification, which can act as a promising carrier protein. Pneumococcal serogroups 14 and 23F were major epidemic causes of pneumococcal infections. In the present study, the capsular PSs (PS14 and PS23F) were conjugated with Hc, TT, and CRM, respectively. TT- and CRM-based conjugates acted as controls for Hc-based conjugates (PS14-Hc and PS23F-Hc). The structural properties of Hc were not fundamentally changed after conjugated with PS. PS14-Hc and PS23F-Hc could potentiate sound PS-specific antibody levels comparable to the controls. Thus, Hc exhibited a practical carrier effect to help the pneumococcal conjugate vaccines perform good immunogenicities.

摘要

encapsulated 细菌,如 type b , 和 ,在全球范围内导致严重的发病率和死亡率。荚膜多糖 (PS) ,它可以引起较弱的 T 细胞非依赖性免疫反应,是一个重要的毒力决定因素。提高 PS 特异性免疫原性的策略之一是将 PS 与无毒载体蛋白结合。破伤风类毒素 (TT) 和 CRM 是 PS 结合疫苗的典型载体蛋白。TT 是用甲醛处理的失活破伤风毒素,存在残留甲醛污染和不完全解毒的问题。CRM 的缺点是产量低,纯化要求复杂的培养条件。因此,非常需要一种没有这些缺点的新型载体蛋白。破伤风毒素天然 C 片段 (Hc) 安全、低成本、免疫原性高,易于纯化,可以作为一种有前途的载体蛋白。肺炎球菌血清型 14 和 23F 是肺炎球菌感染的主要流行原因。在本研究中,分别将荚膜 PS (PS14 和 PS23F) 与 Hc、TT 和 CRM 结合。TT 和 CRM 基缀合物作为 Hc 基缀合物 (PS14-Hc 和 PS23F-Hc) 的对照。PS 结合后 Hc 的结构特性没有根本改变。PS14-Hc 和 PS23F-Hc 可以增强与对照相当的良好 PS 特异性抗体水平。因此,Hc 表现出实际的载体效应,有助于肺炎球菌结合疫苗产生良好的免疫原性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0db98b7de942/MI2020-9596129.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0605cc6fdc34/MI2020-9596129.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0139e4a6f9df/MI2020-9596129.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/485caf07929b/MI2020-9596129.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/1287b2cc4868/MI2020-9596129.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/832fffd0cb5c/MI2020-9596129.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0db98b7de942/MI2020-9596129.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0605cc6fdc34/MI2020-9596129.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0139e4a6f9df/MI2020-9596129.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/485caf07929b/MI2020-9596129.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/1287b2cc4868/MI2020-9596129.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/832fffd0cb5c/MI2020-9596129.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c7/7355367/0db98b7de942/MI2020-9596129.006.jpg

相似文献

1
The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity.肺炎球菌多糖-破伤风类毒素天然 C 片段缀合疫苗:载体效应和免疫原性。
Mediators Inflamm. 2020 Jul 4;2020:9596129. doi: 10.1155/2020/9596129. eCollection 2020.
2
The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine.苯基连接子显著提高了肺炎球菌多糖结合疫苗的免疫原性。
Biotechnol Lett. 2018 Aug;40(8):1263-1270. doi: 10.1007/s10529-018-2575-7. Epub 2018 May 25.
3
Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.一种新型的b型流感嗜血杆菌与C群和Y群脑膜炎奈瑟菌-破伤风类毒素结合疫苗联合接种,不会干扰对美国常规使用的婴儿疫苗中所含抗原的免疫反应。
Hum Vaccin. 2011 Feb;7(2):258-64. doi: 10.4161/hv.7.2.14170. Epub 2011 Feb 1.
4
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.随机试验评估流感嗜血杆菌 b 型和脑膜炎奈瑟菌 C 群、Y 群与破伤风类毒素结合疫苗在婴儿中的免疫原性和安全性。
Pediatr Infect Dis J. 2010 Jan;29(1):48-52. doi: 10.1097/INF.0b013e3181c3ce88.
5
A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components.肺炎球菌结合疫苗成分热稳定性的物理化学评估
Hum Vaccin Immunother. 2014;10(9):2744-53. doi: 10.4161/hv.29696. Epub 2014 Nov 17.
6
Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.破伤风类毒素结合细菌多糖疫苗中载体蛋白识别的结构相关性
Vaccine. 2015 Mar 10;33(11):1345-52. doi: 10.1016/j.vaccine.2015.01.046. Epub 2015 Jan 29.
7
Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.载体蛋白的适度聚乙二醇化可提高A群脑膜炎球菌多糖结合疫苗的多糖特异性免疫原性。
Vaccine. 2015 Jun 22;33(28):3208-14. doi: 10.1016/j.vaccine.2015.04.094. Epub 2015 May 8.
8
Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm.具有长间隔臂的肺炎球菌多糖结合疫苗的研制。
Vaccine. 2013 Nov 19;31(48):5623-6. doi: 10.1016/j.vaccine.2013.09.065. Epub 2013 Oct 9.
9
Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine.聚乙二醇-十六烷的缀合显著提高了肺炎球菌多糖结合疫苗的免疫原性。
Vaccine. 2017 Mar 23;35(13):1698-1704. doi: 10.1016/j.vaccine.2017.02.027. Epub 2017 Feb 24.
10
Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants.b 型流感嗜血杆菌、C 群和 Y 群脑膜炎奈瑟球菌与破伤风类毒素结合疫苗与人类轮状病毒、甲型肝炎和 13 价肺炎球菌结合疫苗联合接种的免疫原性和安全性:一项在婴儿中进行的 III 期、随机、多中心研究结果。
Hum Vaccin Immunother. 2019;15(2):327-338. doi: 10.1080/21645515.2018.1526586. Epub 2018 Oct 5.

引用本文的文献

1
Progress in research and development of preventive vaccines for children in China.中国儿童预防性疫苗的研发进展
Front Pediatr. 2024 Jul 3;12:1414177. doi: 10.3389/fped.2024.1414177. eCollection 2024.
2
Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China.中国江苏对 CRM197 和 TT 载体蛋白 PCV13 的上市后安全性监测。
Front Public Health. 2023 Oct 16;11:1272562. doi: 10.3389/fpubh.2023.1272562. eCollection 2023.
3
Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production.

本文引用的文献

1
Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.预防儿童感染包膜细菌引起的侵袭性感染。
Front Immunol. 2018 Nov 20;9:2674. doi: 10.3389/fimmu.2018.02674. eCollection 2018.
2
Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine.聚乙二醇-十六烷的缀合显著提高了肺炎球菌多糖结合疫苗的免疫原性。
Vaccine. 2017 Mar 23;35(13):1698-1704. doi: 10.1016/j.vaccine.2017.02.027. Epub 2017 Feb 24.
3
Conjugation with an Inulin-Chitosan Adjuvant Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein.
破伤风毒素片段C:结构、药物发现研究与生产
Pharmaceuticals (Basel). 2022 Jun 17;15(6):756. doi: 10.3390/ph15060756.
4
Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 Trial.在中国健康成年人中使用重组破伤风疫苗的安全性和免疫原性:一项随机、双盲、剂量递增、安慰剂和阳性对照的 1/2 期临床试验。
Adv Sci (Weinh). 2021 Aug;8(15):e2002751. doi: 10.1002/advs.202002751. Epub 2021 Jun 3.
与菊粉-壳聚糖佐剂结合显著提高结核分枝杆菌CFP10-TB10.4融合蛋白的免疫原性。
Mol Pharm. 2016 Nov 7;13(11):3626-3635. doi: 10.1021/acs.molpharmaceut.6b00138. Epub 2016 Oct 18.
4
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.肺炎球菌结合疫苗(PCV7和PCV13)对德国两岁以下儿童侵袭性肺炎球菌疾病的有效性
PLoS One. 2016 Aug 15;11(8):e0161257. doi: 10.1371/journal.pone.0161257. eCollection 2016.
5
Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults.成人侵袭性肺炎球菌疾病潜在慢性疾病的风险。
Vaccine. 2016 Aug 5;34(36):4293-7. doi: 10.1016/j.vaccine.2016.07.003. Epub 2016 Jul 7.
6
Serotypes and Antibiotic Susceptibility of Streptococcus pneumoniae Isolates from Invasive Pneumococcal Disease and Asymptomatic Carriage in a Pre-vaccination Period, in Algeria.阿尔及利亚疫苗接种前时期侵袭性肺炎球菌疾病和无症状携带的肺炎链球菌分离株的血清型及抗生素敏感性
Front Microbiol. 2016 Jun 14;7:803. doi: 10.3389/fmicb.2016.00803. eCollection 2016.
7
Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly.23价肺炎球菌多糖疫苗对老年糖尿病患者的有效性
Medicine (Baltimore). 2016 Jun;95(26):e4064. doi: 10.1097/MD.0000000000004064.
8
Comparative Immunogenicity of the Tetanus Toxoid and Recombinant Tetanus Vaccines in Mice, Rats, and Cynomolgus Monkeys.破伤风类毒素和重组破伤风疫苗在小鼠、大鼠和食蟹猴中的免疫原性比较
Toxins (Basel). 2016 Jun 25;8(7):194. doi: 10.3390/toxins8070194.
9
A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens.肺炎球菌疫苗综述:当前多糖疫苗推荐及未来蛋白质抗原
J Pediatr Pharmacol Ther. 2016 Jan-Feb;21(1):27-35. doi: 10.5863/1551-6776-21.1.27.
10
Molecular shape and immunogenicity of meningococcal polysaccharide group A conjugate vaccine.A群脑膜炎球菌结合疫苗的分子形状与免疫原性
Vaccine. 2015 Oct 26;33(43):5815-5821. doi: 10.1016/j.vaccine.2015.09.021. Epub 2015 Sep 19.